SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

          [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended June 30, 2002

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
       For the transition period from .................to.................

                         Commission file number 001-1296

                            ZEVEX INTERNATIONAL, INC.
               (Exact name of registrant as specified in charter)

          DELAWARE                                            87-0462807
-------------------------------                          ------------------
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                           Identification No.)

                4314 ZEVEX Park Lane, Salt Lake City, Utah 84123
              (Address of principal executive offices and zip code)

                                 (801) 264-1001
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
(Former name, former address, and former fiscal year, if changed since last
report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [ X ] No


Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date. As of July 31, 2002, the
Company had outstanding 3,415,197 shares of common stock, par value $0.001 per
share.

<PAGE>
                                     PART I

                              FINANCIAL INFORMATION

-------------------------------------------------------------------------------

               ITEM 1. FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q
-------------------------------------------------------------------------------

ZEVEX International, Inc. ("ZEVEX" or the "Company") files herewith balance
sheets of the Company as of June 30, 2002, and December 31, 2001, and the
related statements of operations and cash flows for the respective three month
and six month periods ended June 30, 2002 and 2001. In the opinion of the
Company's management, the financial statements reflect all adjustments, all of
which are normal recurring adjustments, necessary to fairly present the
financial condition of the Company for the interim periods presented. The
financial statements included in this report on Form 10-Q should be read in
conjunction with the audited financial statements of the Company and the notes
thereto included in the Annual Report of the Company on Form 10-K for the year
ended December 31, 2001.


<PAGE>

                                    ZEVEX INTERNATIONAL, INC.
                                   CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
<S>                                                <C>               <C>    <C>               <C>

                                                            June 30,              December 31,
                                                              2002                    2001
                                                           (unaudited)
                                                    ----------------------  ----------------------
          ASSETS

Current assets
     Cash and cash equivalents                                $ 1,268,793             $ 1,028,086
     Restricted cash for sinking fund payment on IDB               35,452                  93,076
     Accounts receivable, net                                   4,085,555               5,748,578
     Inventories                                                6,472,499               7,272,842
     Marketable securities                                              -                 219,899
     Deferred income taxes                                        332,056                 568,387
     Income taxes receivable                                      385,543                 418,506
     Prepaid expenses and other current assets                   215,386                  62,662
                                                                 --------                 ------
     Total current assets                                      12,795,284              15,412,036

     Property and equipment, net                                7,147,091               7,688,088
     Patents, trademarks and acquisition costs, net               328,091                 342,746
     Goodwill, net                                             10,154,757              10,154,757
     Other assets                                                 58,440                  41,519
                                                                  -------                 ------
     Total assets                                            $30,483,663             $33,639,146
                                                             ============            ===========

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
     Accounts payable                                           $ 901,341             $ 1,711,429
     Other accrued expenses                                       612,521                 563,067
     Bank line of credit                                           69,794               1,713,610
     Current portion of industrial development bond               100,000                 100,000
     Payable related to business acquisition and
        convertible debt, short-term                            3,735,172               1,143,390
     Current portion of other long-term debt                    1,465,496                 524,381
     Current portion of capital leases                           170,270                 162,783
                                                                 --------                -------
     Total current liabilities                                  7,054,594               5,918,660

     Deferred income taxes                                        266,252                 276,734
     Industrial development bond                                1,400,000               1,500,000
     Convertible debt, long-term                                        -               3,001,970
     Other long-term debt                                         409,430               1,608,330
     Capital lease obligation                                     214,003                 301,051

STOCKHOLDERS' EQUITY
     Common stock; $.001 par value, authorized
        10,000,000 shares, 3,440,197 issued and 3,415,197
        outstanding at June 30, 2002 and December 31, 2001          3,440                   3,440
     Additional paid in capital                                16,290,452              16,290,452
     Unrealized gain on marketable securities, net                      -                  20,177
     Treasury stock, 25,000 shares at cost                       (60,956)                (60,956)
     Retained earnings                                          4,906,448               4,779,288
                                                               ----------              ---------
     Total stockholders' equity                                21,139,384              21,032,401
                                                              -----------              ----------
     Total liabilities and stockholders' equity               $30,483,663             $33,639,146
                                                             ============             ===========
</TABLE>


<PAGE>




                            ZEVEX INTERNATIONAL, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
<S>                                                   <C>         <C>     <C>                 <C>                    <C>         <C>

                                                                Three months ended                        Six months ended
                                                                     June 30,                                 June 30,
                                                            2002             2001                 2002                       2001
                                                         (unaudited)      (unaudited)          (unaudited)               (unaudited)
                                                     ------------------   --------------      --------------          --------------
                                                     ------------------   --------------      --------------          --------------
Revenue:
     Product sales                                        $ 5,500,621     $ 7,259,523         $ 11,428,552              $ 14,290,970
     Engineering services                                     303,820         311,109              471,543                   672,081
                                                             --------        --------             --------                   -------
     Total revenue                                          5,804,441       7,570,632           11,900,095                14,963,051

     Cost of sales                                          3,543,255       4,829,581            7,199,256                 9,332,303
                                                           ----------      ----------           ----------                 ---------
Gross profit                                                2,261,186       2,741,051            4,700,839                 5,630,748

Operating expenses:
     General and administrative                             1,498,434       1,512,462            2,964,838                 3,048,452
     Selling and marketing                                    594,907         684,764            1,274,926                 1,325,541
     Research and development                                  48,837          83,914              128,416                   206,174
     Goodwill amortization                                          -         133,358                    -                   266,634
                                                                   --        --------                   --                   -------
Total operating expenses                                    2,142,178       2,414,498            4,368,180                 4,846,801

Operating income                                              119,008         326,553              332,659                   783,947

Other income (expense):
     Interest and other income                                 12,585           2,266               13,189                     3,592
     Interest expense                                        (155,970)       (277,065)           (306,608)                 (586,271)
     Gain on sale of marketable securities                          -               -               38,079                    40,978
                                                                   --              --              -------                    ------
Income (loss) before income taxes                             (24,377)         51,754               77,319                   242,246

Benefit (provision for) income taxes                            29,161        (62,202)              49,841                 (165,233)
                                                               -------       --------              -------                 ---------

Net income (loss)                                              $ 4,784      $ (10,448)           $ 127,160                  $ 77,013
                                                              ========      ==========           ==========                 ========


Basis net income (loss) per share                               $ 0.00        $ (0.00)               $ 0.04                   $ 0.02
                                                                =======       ========               =======                  ======

Weighted average shares outstanding                           3,415,197      3,440,197             3,415,197               3,440,197
                                                              ==========     ==========           ==========               =========

Diluted net income (loss) per share                               $ 0.00       $ (0.00)               $ 0.04                  $ 0.02
                                                                 =======       ========              =======                  ======

Diluted weighted average shares outstanding                    3,420,105      3,440,197            3,419,820               3,448,957
                                                              ==========     ==========           ==========               =========

</TABLE>


<PAGE>




                            ZEVEX INTERNATIONAL, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
<S>                                                                         <C>              <C>    <C>                <C>
                                                                                             Six months ended
                                                                                                 June 30,
                                                                                     2002                     2001
                                                                            ----------------------   ---------------------
                                                                            ----------------------   ---------------------
Cash flows from operating activities                                               $ 127,160                $ 77,013
Adjustments to reconcile net income to net cash provided
   by operating activities
     Depreciation and amortization                                                   797,797               1,029,141
     Deferred income taxes                                                           237,853                  45,015
     Realized gain on marketable securities                                         (38,079)                (40,978)
     Changes in operating assets and liabilities:
        Restricted cash for sinking fund payment
           on industrial development bond                                             57,624                  56,200
        Accounts receivable                                                        1,663,023               1,270,615
        Inventories                                                                  800,343               1,223,642
        Prepaid expenses                                                            (152,724)                 (2,987)
        Other assets                                                                 (16,921)                  9,236
        Accounts payable                                                            (810,088)               (613,093)
        Accrued and other liabilities                                                  49,454                 (1,869)
        Income taxes receivable/payable                                                32,963                   2,983
                                                                                      -------                   -----

Net cash provided by operating activities                                           2,748,405               3,054,918
                                                                                    ----------              ---------

Cash flows from investing activities
Purchase of property and equipment                                                   (242,145)               (807,684)
Additions of patents and trademarks                                                         -                  (6,338)
Redemption of available-for-sale marketable securities                                 225,797                 127,221
                                                                                      --------                 -------

Net cash used in investing activities                                                 (16,348)               (686,801)
                                                                                      --------               ---------

Cash flows from financing activities
Proceeds from capital lease and long-term debt                                               -               2,500,000
Payments on capital lease and long-term debt                                          (337,346)               (193,896)
Payments on business acquisition debt                                                 (410,188)                      -
Repayment on industrial development bond                                              (100,000)               (100,000)
Repayment of bank line of credit                                                    (1,643,816)             (4,077,256)
Proceeds from exercise of stock options                                                      -                      665
                                                                                            --                      ---

Net cash used in financing activities                                               (2,491,350)             (1,870,487)
                                                                                    -----------             -----------

Net increase in cash and cash equivalents                                               240,707                 497,630

Cash and cash equivalents at beginning of period                                      1,028,086                 327,157
                                                                                     ----------                 -------

Cash and cash equivalents at end of period                                          $ 1,268,793               $ 824,787
                                                                                    ============               =========


Supplemental disclosure:
Non-cash activities
Unrealized loss on available-for-sale marketable securities                                $ -                $ (23,201)
                                                                                           ====               ==========
</TABLE>



<PAGE>

                            ZEVEX INTERNATIONAL, INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                  June 30, 2002

1.  Summary of Significant Accounting Policies

Description of Organization and Business

The Company was incorporated under the laws of the State of Nevada on December
30, 1987. The Company was originally incorporated as Downey Industries, Inc. and
changed its name to ZEVEX International, Inc. on August 15, 1988. In November
1997, the Company reincorporated in Delaware. In December 1998, the Company
acquired an additional product line and completed the acquisition of two
additional subsidiaries. Additionally, the Company acquired a product line from
Nestle USA, Inc. in April of 2000. The Company, through its divisions and
subsidiaries, engages in the business of designing, manufacturing and
distributing medical devices. Recently, ZEVEX renamed its three primary business
divisions. Its Applied Technology business division designs and manufactures
advanced medical components and systems for other medical technology companies
through its ZEVEX, Inc. subsidiary. Its Physical Evaluation business division
designs, manufactures and markets industry leading physical evaluation testing
systems though its JTech Medical Industries, Inc. subsidiary. Its Therapeutics
business division designs, manufactures and markets enteral nutrition delivery
devices through its ZEVEX, Inc. subsidiary.

Principles of Consolidation


The consolidated financial statements at June 30, 2002 include the accounts of
the Company and its wholly owned operating subsidiaries: ZEVEX, Inc. and JTech
Medical Industries, Inc. (JTech). The consolidated statement of operations for
the three months and six months ended June 30, 2001 also includes the results of
operations of its former subsidiary, Aborn Electronics, Inc. (Aborn). During
December 2001, the corporate shell of Aborn was sold to a related party. The
Company retained certain manufacturing rights, cash, accounts receivable,
equipment, and inventory, which now are included within the subsidiary, ZEVEX,
Inc. For additional information regarding this transaction refer to the
Company's 2001 Annual Report on SEC Form 10-K. All significant intercompany
balances and transactions have been eliminated in consolidation.


Basis of Presentation

The accompanying financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information along
with the instructions to Form 10-Q of Regulation S-X. Accordingly, certain
information and footnote disclosures normally included in complete financial
statements have been condensed or omitted. These financial statements should be
read in conjunction with the financial statements and footnotes thereto included
in the Company's 2001 Annual Report on SEC Form 10-K.


In the opinion of management, all adjustments (consisting of normal and
recurring adjustments) considered necessary for a fair presentation have been
included. The results of operations for interim periods may not be indicative of
the results of operations to be expected for a full year.


New Accounting Pronouncements

In June 2001, the FASB issued SFAS No. 141, Business Combinations, and No. 142,
Goodwill and Other Intangible Assets.

SFAS No. 141 requires that the purchase method of accounting be used for all
business combinations initiated after June 30, 2001. Use of the
pooling-of-interests method is no longer permitted. SFAS No. 141 also includes
guidance on the initial recognition and measurement of goodwill and other
intangible assets acquired in a business combination that is completed after
June 30, 2001.

SFAS No. 142 no longer permits the amortization of goodwill and indefinite-lived
intangible assets. Instead, these assets must be reviewed annually (or more
frequently under certain conditions) for impairment in accordance with this
Statement. This impairment test uses a fair value approach, rather than the
undiscounted cash flows approach previously required by SFAS No. 121. Intangible
assets that do not have indefinite lives will continue to be amortized over
their useful lives and reviewed for impairment in accordance with SFAS No. 121
or SFAS No. 144 (see below). The Company has adopted SFAS No. 142 effective
January 1, 2002. SFAS No. 142 provides a six-month period from the effective
date of adoption for the Company to complete Step 1 (determining and comparing
the fair value of the Company's reporting units to their carrying values) of the
transitional impairment test. Step 2 involves the calculation of the implied
fair value of goodwill and must be completed by December 31, 2002. The Company
has completed Step 1 of the impairment assessment. Based upon the Company's
valuation procedures, the Company has determined that the fair value of the
reporting units exceeds the carrying value including goodwill, as such the
Company is not required to complete Step 2 of the impairment assessment and no
impairment loss is recognized.

As of June 30, 2002, the Company's gross goodwill balance is $11,603,600 with
accumulated amortization of $1,448,843. The adoption of SFAS No. 142 will reduce
the Company's amortization expense by approximately $533,000 annually beginning
in 2002, due to the nonamortization of goodwill. Amortization expense for
goodwill for the three months ended June 30, 2001 was $133,358, and $266,634 for
the six months ended June 30, 2001. Adjusted net income and net income per
common share for the three and six months ended June 30, 2001 compared to the
actual results for the three and six months ended June 30, 2002 is as follows:

<TABLE>
<CAPTION>
<S>                                       <C>                 <C>                <C>           <C>   <C>          <C>


                                             For Three Months Ended June 30          For Six Months Ended June 30
                                                2002                2001               2002               2001
                                          ------------------ ------------------- ------------------ ------------------
                                          ------------------ ------------------- ------------------ ------------------
Reported net income (loss)                         $  4,784          $ (10,448)          $ 127,160           $ 77,013
Goodwill amortization                                    --             133,358                 --            266,634
                                          -----------------             -------  -----------------            -------
Adjusted net income                                $  4,784           $ 122,910          $ 127,160          $ 343,647
                                                   ========           =========          =========          =========

Basic net income per share reported                 $   .00             $   .00            $   .04            $   .02
Goodwill amortization                                    --                 .04                 --                .08
                                          -----------------       -------------    -----------------     -------------
Adjusted                                            $   .00             $   .04            $   .04            $   .10
                                                    =======             =======            =======            =======

Diluted net income per share reported               $   .00             $   .00            $   .04            $   .02
Goodwill amortization                                    --                 .04                 --                .08
                                          -----------------  -------------  ---  -----------------  ------------- ---
Adjusted                                            $   .00             $   .04            $   .04            $   .10
                                                    =======             =======            =======            =======
</TABLE>

In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets. This Statement addresses financial accounting and
reporting for the impairment or disposal of long-lived assets. This Statement
supersedes SFAS No. 121, and the accounting and reporting provisions of APB
Opinion No. 30, Reporting the Results of Operations and Reporting the Effects of
Disposal of a Segment of a Business, and Extraordinary, Unusual, and
Infrequently Occurring Events and Transactions, for the disposal of a segment of
business (as previously defined in that Opinion). The Company adopted SFAS No.
144 effective January 1, 2002. As expected, the adoption of SFAS No. 144 did not
have a material impact on the consolidated financial position, consolidated
results of operations or liquidity of the Company.


In April 2002, SFAS No. 145, "Rescission of FASB Statements No. 4, 44 and 64,
Amendment of FASB Statement No. 13, and Technical Corrections" was issued. This
statement provides guidance on the classification of gains and losses from the
extinguishment of debt and on the accounting for certain specified lease
transactions. It is not anticipated that the adoption of this statement will
have a material impact on the consolidated financial position, consolidated
results of operations or liquidity of the Company.


In June 2002, SFAS No. 146, "Accounting for Costs Associated with Exit or
Disposal Activities" was issued. This statement provides guidance on the
recognition and measurement of liabilities associated with disposal activities
and is effective for the Company on January 1, 2003. It is not anticipated that
the adoption of this statement will have a material impact on the consolidated
financial position, consolidated results of operations or liquidity of the
Company.

2.  Bank Line of Credit

In 2002, the Company renewed its line of credit arrangement with a financial
institution with availability of $6 million. The line matures on May 28, 2003.
The line of credit is collateralized by accounts receivable and inventory and
bears interest at the prime rate, which was 4.75% at June 30, 2002 and December
31, 2001. The Company's balance on its line of credit was $69,794 at June 30,
2002 and $1,713,610 at December 31, 2001. Under the line of credit agreement,
the Company is restricted from declaring cash dividends. In addition, the
Company's line of credit contains certain financial covenants.

3.  Related Party Transactions

On December 31, 1998, the Company acquired JTech pursuant to a Stock Purchase
Agreement among the Company and the four shareholders of JTech (the "JTech Stock
Purchase"). Leonard C. Smith, one of the selling JTech shareholders, received
$1,311,188 in cash and a convertible debenture in connection with the JTech
Stock Purchase. The Company paid $290,000 of the convertible debenture in
December 2001, and the remaining principal amount of $1,073,594 (inclusive of
the 1999 earn-out provision of $73,594 which was paid on April 2, 2002) is due
January 6, 2003 (as modified in December 2001) and is convertible to common
stock at Mr. Smith's option during the period from January 6, 2000 to January 6,
2003 at $11 per share.

4.   Comprehensive Income

Effective January 1, 1998, the Company adopted Statement of Financial Accounting
Standards ("SFAS") No. 130, "Reporting Comprehensive Income". SFAS No. 130
requires that all items recognized under accounting standards as components of
comprehensive income be reported in an annual financial statement that is
displayed with the same prominence as other annual financial statements. This
statement also requires that an entity classify items of other comprehensive
income by their nature in an annual financial statement. Other comprehensive
income may include foreign currency translation adjustments, and unrealized
gains and losses on marketable securities classified as available-for-sale. For
the three months and six months ending June 30, 2002, the Company did not have
any other elements of comprehensive income. Therefore, comprehensive income
equaled net income. For the three months ending June 30, 2001, the Company's
comprehensive loss was $2,172 (net of tax effect) less than the net loss
reported on the Company's financial statements. For the six months ending June
30, 2001, the Company's comprehensive income was $14,546 (net of tax effect)
lower than net income reported on the Company's financial statements.

5. Inventories
<TABLE>
<CAPTION>
<S>                                                   <C>                                   <C>
Inventories consist of the following:
                                                        June 30, 2002      December 31, 2001
                                                      ------------------------------------------

Materials                                                $    2,903,756     $    3,355,793
Work in progress                                              1,225,786          1,241,034
Finished goods, including completed subassemblies             2,342,957          2,676,015
                                                      ------------------------------------------
                                                         $    6,472,499     $    7,272,842
                                                      ==========================================
</TABLE>


6. Net Income Per Common Share

Basic net income per common share is calculated by dividing net income for the
period by the weighted-average number of the Company's common shares
outstanding.

Diluted net income per common share includes the dilutive effect of options in
the weighted-average number of the Company's common shares outstanding as
calculated using the treasury stock method.


<PAGE>


-------------------------------------------------------------------------------

                 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
-------------------------------------------------------------------------------


General


ZEVEX, through its divisions and subsidiaries, engages in the business of
designing, manufacturing and distributing medical devices. Recently, ZEVEX
renamed its three primary business divisions. Its Applied Technology business
division designs and manufactures advanced medical components and systems for
other medical technology companies. Its Physical Evaluation business division
designs, manufactures and markets industry leading physical evaluation testing
systems. Its Therapeutics business division designs, manufactures and markets
award-winning enteral nutrition delivery devices. See Note 1 of the Financial
Statements, Description of Organization and Business for more information.


Results of Operations


ZEVEX' revenues for the second quarter of 2002 decreased to $5,804,441 from
$7,570,632 for the second quarter of 2001, a decrease of approximately 23%. For
the first six months of 2002, revenue decreased 20% to $11,900,095 from
$14,963,051 for the six months ended June 30, 2001. In the second quarter of
2002, 66% of ZEVEX' revenue was derived from proprietary products sold by ZEVEX,
in comparison to 58% in 2001, and 62% for the first six months of 2002, compared
to 60% for the six months ended June 30, 2001. Sales of ZEVEX' Therapeutic
business products accounted for approximately 50% of total revenues for the
three months ended June 30, 2002, compared to 45% for the three months ended
June 30, 2001, and 47% for the first six months of 2002, compared to 48% for the
six months ended June 30, 2001. Sales of ZEVEX' Physical Evaluation products
accounted for approximately 15% of total revenues for the three months ended
June 30, 2002, compared to 13% for the three months ended June 30, 2001, and 15%
for the first six months of 2002, compared to 12% for the six months ended June
30, 2001. Thirty-five percent of ZEVEX' revenues during the second quarter 2002
were derived from its Applied Technology business, compared to 42% in 2001, and
38% for the first six months of 2002, compared to 40% for the six months ended
June 30, 2001.

The decrease in revenues for the second quarter of 2002 and for
the first six months of 2002 is largely due to (1) the delay of several orders
for contract-manufactured products, including those related to a customer during
its corporate reorganization through a spin-off from its parent, a customer
which has been reducing inventory levels and safety stock, and a customer which
has delayed orders due to technical issue not involving ZEVEX, (2) the
scheduling of private-label enteral feeding pump orders for a European customer,
and (3) decline in orders for stationary enteral nutrition delivery pump
disposable sets. As of the date of this report, however, scheduled shipments of
surgical handpieces have increased compared to the first six months of 2002, and
the Company has experienced an increase in orders for private label enteral
feeding pumps from the European customer mentioned above.  The Company recently
began a new time and materials development program for a mobile organ perfusion
system.  Additionally, the Company is also in the process of completing the
development of three new surgical handpieces, which it expects will be followed
by production orders.  The Company is also currently developing several new
ultrasonic and optoelectronic products for certain customers.  While these
developments are encouraging, there is no assurance that the products and
applications under development will result in manufacturing sales for the
Company.  Additionally, because scheduled shipments may in certain cases be
cancelled or postponed without penalty, improvements in scheduled shipments may
prove to be temporary and not continue for the remainder of the Company's fiscal
year.


ZEVEX' gross profit as a percentage of revenues was approximately 39% for the
second quarter of 2002, compared to 36% for the second quarter of 2001. Gross
profit for the six months ended June 30, 2002 was approximately 40% compared to
38% for the same six month period of 2001. Management attributes the slight
increase in gross profit percentage from 2001 to 2002 to the particular product
mix delivered during the quarter.


Selling, general and administrative expenses decreased slightly during the
second quarter of 2002 to $2,093,341, as compared to $2,197,226, for the second
quarter of 2001. For the six months ended June 30, 2002 selling, general and
administrative expenses decreased to $4,239,764, as compared to $4,373,993 for
the same six month period of 2001.  The Company is continuing its investment in
building its domestic sales force for the Physical Evaluation and Therapeutics
divisions, and its efforts to grow international sales of all product lines.


As of June 30, 2002, ZEVEX had two full-time engineers engaged in research and
development, and had several other designers and engineers, including
independent contractors, contributing to research and development projects.
During the second quarter of 2002, ZEVEX invested $48,837 in research and
development, compared to $83,914 in the second quarter 2001. For the six months
ended June 30, 2002, ZEVEX invested $128,416 in research and development,
compared to $206,174 for the six months ended June 30, 2001. The Company is
continuing its efforts to develop and introduce new proprietary products and is
currently planning new product introductions during the next fiscal year.
Additionally, the Company is investing in developing proprietary component
technologies for its contract manufacturing services.   Management anticipates
that research and development expenses for 2002 will be approximately 2% of
total revenues.


For the second quarter of 2002, ZEVEX had net income of $4,784, 0.1% of revenues
compared to a net loss of $10,448, for the second quarter of 2001. The increase
in net income during the second quarter of 2002, as compared to the second
quarter of 2001, is due to a number of factors, including, (1) higher gross
profit associated with the ZEVEX' product mix (2) a reduction in interest
expense from $277,065 to $155,970, due to decreased debt and interest rates, (3)
nonamortization of goodwill amortization under SFAS No. 142, which was adopted
as of January 1, 2002. However, the impact of these cost reductions was reduced
by lower revenue during the second quarter of 2002. Net income for the six
months ended June 30, 2002, increased to $127,160, or 1.0% of revenues, from
$77,013, or 0.5% of revenues for the six months ended June 30, 2001. The
increase in net income during the first six months of 2002, as compared to the
first six months of 2001, is due to a number of factors, including, (1) higher
gross profit associated with the ZEVEX' product mix, (2) a reduction in interest
expense from $586,271 to $306,608, due to decreased debt and interest rates, (3)
nonamortization of goodwill amortization under SFAS No. 142, which was adopted
as of January 1, 2002, (4) the tax benefit derived from a capital loss which,
for the State of Utah, was treated as a net operating loss carryback for income
tax purposes. However, the impact of these cost reductions was reduced by lower
revenue during the first half of 2002.

Depreciation and amortization expenses decreased to $401,430 in the second
quarter 2002 from $513,886 in the second quarter 2001, and to $797,797 for the
first six months of 2002, from $1,029,141 for the first six months of 2001. The
decrease is due to the elimination of goodwill amortization as of January 1,
2002 with the adoption of SFAS No. 142. See Note 2 of the Financial Statements
for more information on the effect of this change.

ZEVEX had an income tax benefit of $29,161 in the second quarter of 2002
compared to an income tax expense of $62,202 for the first quarter of 2001. The
decrease from 2001 to 2002 is primarily due to a refund generated by a capital
loss that was treated as a net operating loss for state income tax purposes.

As of June 30, 2002, ZEVEX' backlog of customer orders was $3,716,000, as
compared to $5,754,000 on June 30, 2001. Management estimates that approximately
90% of the backlog will be shipped before December 31, 2002. During the first
half of 2002, some of ZEVEX' contract manufacturing customers have shortened
their forecasting visibility and subsequently, the schedule of deliveries on
each purchase order. Management does not believe that this reflects an overall
decrease in demand, and is only an indication that some customers are
controlling inventory expense. ZEVEX' backlog is for contract manufacturing only
and can be significantly affected by the timing of annual or semi-annual
purchase orders placed by its customers.

Liquidity and Capital Resources

ZEVEX' primary sources of liquidity have consisted of cash flow from operations,
borrowings under its revolving line of credit and other financial arrangements
described below. In prior years, ZEVEX also has increased working capital
through the issuance of stock and may do so in the future.

Cash flows provided from operating activities for the first six months of 2002
were $2,748,405 compared to cash flows provided from operating activities for
the first six months of 2001 of $3,054,918. In 2002, cash provided by operating
activities was primarily associated with reduction of accounts receivable due to
improved collection procedures and reduction in inventories as ZEVEX recognized
the benefit of its manufacturing resource planning software.

ZEVEX' working capital at June 30, 2002 was $5,740,690, compared to $7,221,255
at June 30, 2001. ZEVEX' decrease in working capital was primarily due to the
reduction in current assets of accounts receivable and inventories used for debt
reduction and the classification as current of the Term Loan secured by its
manufacturing facility because it is due May 15, 2003. The portion of working
capital represented by cash and short-term investments at such dates was
$1,268,793, and $824,787 respectively. The ratio of current assets to current
liabilities increased to 1.81 to 1 at June 30, 2002, from 1.70 to 1 at June 30,
2001.

ZEVEX has a $6,000,000 open line of credit arrangement with a financial
institution. The line matures on May 28, 2003. The line of credit is
collateralized by accounts receivable and inventories, and bears interest at the
financial institution's prime rate. ZEVEX owed $69,794 on the line of credit at
June 30, 2002 and $1,713,610 at December 31, 2001. Management expects to renew
the existing line of credit upon its expiration.


On March 29, 2000, the Company entered into an agreement to acquire certain
assets from Nestle USA, Inc. relating to Nestle's enteral nutrition delivery
devices. The purchase was completed on April 6, 2000 for a purchase price of
approximately $2.6 million, plus the actual cost of inventory acquired by the
Company, which totaled approximately $1.2 million. Upon closing, cash of
approximately $600,000 was paid. An additional $2.2 million was paid in October
2000, which included $1.2 million for inventory. The remainder of the purchase
price, approximately $1,000,000, was calculated based upon the sales generated
by the acquired assets of which approximately $778,000 was paid in July 2001.
The remainder of the balance will be paid upon resolution of certain
contingencies.

On March 15, 2001, ZEVEX entered into a Secured Financing Agreement with a bank
for the amount of $1,500,000. The agreement is secured by ZEVEX' enteral feeding
pumps, which were purchased from Nestle and are now manufactured by ZEVEX. The
proceeds from the agreement were used to reduce ZEVEX' line of credit balance.
The agreement has a 36-month term, is due on February 15, 2004, and bears
interest at a rate of 8.24%. ZEVEX owed $919,532 on the agreement at June 30,
2002.

On April 18, 2001, ZEVEX entered into a Term Loan Agreement with a bank for the
amount of $1,000,000. The agreement is secured by ZEVEX' manufacturing facility.
The proceeds from the Promissory Note were used to reduce ZEVEX' line of credit
balance. The note is due on May 15, 2003 and is amortized over a fifteen-year
term at the interest rate of 8.5%. ZEVEX owed $956,272 on the Term Loan
Agreement at June 30, 2002.

In 1997, ZEVEX completed construction of its new 51,000 square foot headquarters
and manufacturing facility. The cost of this undertaking was approximately
$2,591,177. In 1996, ZEVEX negotiated a $2.0 million Industrial Development Bond
("IDB") to finance this construction. As of June 30, 2002, the remaining
principal balance on the IBD was $1,500,000. During the first the first six
months of 2002, the interest paid monthly ranged from 1.45% to 2.03% (APR).

ZEVEX, in conjunction with certain 1998 business acquisitions, issued
convertible debentures in the aggregate amount of $5,447,188. As of June 30,
2002 the remaining balance on the debentures was $3,512,970. The principle
payments on the debentures will be paid in the following amounts, $258,000 was
paid in July 2002, $258,000 to be paid in October 2002, $2,046,970 in January
2003, and the remaining balance of $950,000 in April 2003. All or part of the
outstanding principal of each debenture is convertible at the holder's option
into ZEVEX' Common Stock at a rate of $11.00 per share at any time prior to
maturity of the debentures.


ZEVEX' purchases of leasehold improvements to its facilities, self-constructed
enteral feeding pumps, MRP software system and new engineering, production and
testing equipment, and tooling totaled $242,145 for the first six months of
2002, compared to $807,684 for the first six months of 2001. ZEVEX expects to
spend approximately $500,000 during the remainder of 2002 for additional
manufacturing equipment and software, for normal replacement of aging equipment,
equipment for lease, and manufacturing tooling related to its proprietary
products. ZEVEX also expects to invest approximately $400,000 in the research
and development of new proprietary products during the second half of 2002.

ZEVEX' expected principal liquidity requirements are working capital,
investments in capital expenditures, and convertible debt reduction. ZEVEX
believes its sources of liquidity are sufficient for operations during the
coming twelve months with its projected cash flows from operations and if
necessary, the availability of funds under its revolving line of credit.

Critical Accounting Policies

ZEVEX has not had  significant  changes to its  accounting  policies with the
exception of the adoption of SFAS No. 142,  "Goodwill and Other Intangible
Assets," and SFAS No. 144, "Accounting for the Impairment or Disposal of Long-
Lived Assets."

Under SFAS No. 142, ZEVEX no longer amortizes its goodwill. However, ZEVEX is
required to assess goodwill for impairment at least annually at a level within
ZEVEX referred to as a reporting unit, as defined by SFAS No. 142. Impairment of
goodwill is deemed to exist when the carrying amount of the goodwill for the
reporting unit exceeds its implied fair value. In order to determine if such
impairment exists, ZEVEX is required to complete Step 1 (determining and
comparing the fair value of the reporting units to the reporting units' carrying
value) impairment test. In the year of adoption, ZEVEX is required to complete
Step 1 within six months of adopting SFAS No. 142. If Step 1 of the goodwill
impairment test is failed in any of ZEVEX' reporting units, thereby indicating a
potential impairment, ZEVEX is required to complete Step 2 of the impairment
test as soon as possible. In the year of adoption, this is required to be
completed no later than the end of the year of adoption (December 31, 2002 for
ZEVEX). Under Step 2, ZEVEX is required to calculate the implied fair value of
goodwill and compare it to the carrying value of goodwill. ZEVEX has completed
Step 1 of the impairment assessment. Based upon ZEVEX' valuation procedures,
ZEVEX has determined that the fair value of the reporting units exceeds the
carrying value including goodwill, as such ZEVEX is not required to complete
Step 2 of the impairment assessment and no impairment loss is recognized.

Under SFAS No. 144, ZEVEX evaluates its long-lived assets other than goodwill
(amortizable intangible assets, property, plant and equipment, and other such
assets) for impairment. In order to perform this evaluation, ZEVEX groups its
long-lived assets with other assets and liabilities at the lowest level for
which identifiable cash flows are largely independent of the cash flows of other
assets and liabilities. Consistent with SFAS No. 121, ZEVEX continues to
consider whether indicators of impairment of long-lived assets are present. If
indicators exist, ZEVEX determines whether the sum of the estimated undiscounted
future cash flows attributable to the assets in question are less than their
carrying amount. If so, ZEVEX recognizes an impairment loss based on the excess
of the carrying amount of the assets over their respective fair values. ZEVEX
currently has no indicators of impairment of any of its long-lived assets.

Other

As part of a nationwide investigation into billing practices associated with
enteral nutrition delivery products, particularly in regard to billing practices
for pumps and disposable delivery sets, on July 2, 2001, the Office of Inspector
General (OIG), served a subpoena on ZEVEX' ZEVEX, Inc. subsidiary. According to
published reports, the investigation involved most manufacturers, distributors
and health care service providers in the United States enteral pump industry and
similar subpoenas were served on many of those parties. The subpoena requested
Company documents relating to its enteral pump customers, marketing and billing
practices. ZEVEX has responded to the subpoena and it is cooperating with the
investigation. At this time ZEVEX is uncertain as to any future impact this
investigation will have on its operations or financial position.


Cautionary Statement for Purposes of "Safe Harbor Provisions" of the Private
Securities Litigation Reform Act of 1995


When used in this report, the words such as "estimate," "believe," "project,"
"anticipate" and similar expressions, together with other discussion of future
trends or results, are intended to identify forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended (the
"Securities Act") and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). Such statements, which include the Company's
statements about the level of anticipated expenses during 2002 and its liquidity
position are subject to certain risks and uncertainties, including those
discussed below that could cause actual results to differ materially from those
projected. These forward-looking statements speak only as of the date hereof and
the Company disclaims any obligation to update them. All of these
forward-looking statements are based on estimates and assumptions made by
management of the Company, which although believed to be reasonable, are
inherently uncertain and difficult to predict. Therefore, undue reliance should
not be placed upon such estimates. There can be no assurance that the benefits
anticipated in these forward-looking statements will be achieved. The following
important factors, among others, could cause the Company not to achieve the
benefits contemplated herein, or otherwise cause the Company's results of
operations to be adversely affected in future periods: (i) continued or
increased competitive pressures from existing competitors and new entrants; (ii)
unanticipated costs related to the Company's growth and operating strategies;
(iii) loss or retirement of key members of management; (iv) increase in interest
rates of the Company's cost of borrowing, or a default under any material debt
agreement; (v) adverse state or federal legislation or regulation that increases
the cost of compliance, or adverse findings by a regulator with respect to
existing operations; (vi) loss of customers; (vii) inability to achieve future
sales; (viii) the unavailability of sufficient funds for operations or capital
expenditures; and (ix) inability to introduce new products as planned. Many of
such factors are beyond the control of the Company. Please refer to the
Company's SEC Form 10-K for its fiscal year ended December 31, 2001 for
additional cautionary statements.



-------------------------------------------------------------------------------

                 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE
                                ABOUT MARKET RISK
-------------------------------------------------------------------------------

No significant changes in market risk have occurred since December 31, 2001.
Please refer to the Company's SEC Form 10-K for its fiscal year ended December
31, 2001 for additional discussions on market risks.


<PAGE>


                                     PART II

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

         The following exhibits are attached hereto or are incorporated herein
by reference as indicated in the table below:

         Exhibit                                   Location if other
          No.     Title of Document                than attached hereto
         ------   -----------------                --------------------

         3.01*    Certificate of Incorporation     Amendment No. 1 to Form S-1,
                                                   filed October 24, 1997

         3.02*    Amended Bylaws                   March 31, 2002 Form 10Q
                                                   filed May 10, 2002

         (b)      Reports on Form 8-K

                  No reports on Form 8-K were filed by the Company during the
quarter ended June 30, 2002.


* Denotes  exhibits  specifically  incorporated  in this  Form 10-Q by
reference  to other  filings  of the  Company  pursuant  to the provisions  of
Securities  and  Exchange  Commission  rule 12b-32 and  Regulation  S-K.  These
documents  are located  under File No. 001-10287 at, among other locations,  the
Securities and Exchange Commission,  Public Reference Branch, 450 5th St., N.W.,
Washington, D.C. 20549.

-------------------------------------------------------------------------------

                                   SIGNATURES
-------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

ZEVEX INTERNATIONAL, INC.

Dated:  August 8, 2002
                                     By   /s/ David J. McNally
                                         --------------------------
                                         David J. McNally, CEO
                                        (Chief Executive Officer)

                                     By  /s/ Phillip L. McStotts
                                        ------------------------------
                                        Phillip L. McStotts, Secretary
                                        (Principal Financial Officer)
<PAGE>